Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
Search Criteria
Gene/CloneSpeciesStageAnatomy ItemExperimenter
myod1xenopus   

Too many results?Too few results?

Experiment details for myod1

Hanel ML et al. (2009) Assay

Muscular dystrophy candidate gene FRG1 is critical for muscle development.

Gene Clone Species Stages Anatomy
myod1.S laevis NF stage 18 paraxial mesoderm
myod1.S laevis NF stage 33 and 34 mesoderm , paraxial mesoderm , myotome , epaxial muscle , intersomitic region

Display additional annotations [+]
  Figure 4. Decreased expression of myotome markers, decreased segmentation, and loss of hypaxial muscle in FRG1-depleted embryos. A,B: Stage 18 embryos injected (i, injected side) with either 40 ng of FMO1 or 40 ng of CMO respectively, stained for pax3 (dm dermomytome). C: Transverse section of a pax3-stained embryo injected with 40 ng of FMO1 showing less organized pax3 expression on the injected side (i) in the dermomyotome (arrowheads). D,E: myoD staining of stage 18 embryos injected with 20 ng of FMO1 and 40 ng of CMO, respectively. F: Graph showing percent stage 20 embryos with reduced pax3 in the dermomyotome and diffuse myoD staining. G,H: pax3 staining of injected (i) and uninjected sides of stage 34 embryos injected with 20 ng of FMO1, with close-up view of hypaxial muscle region. J,K: myoD staining of injected and uninjected sides of stage 34 embryos injected with 20 ng of FMO1. I,L: pax3 and myoD staining, respectively, of embryos injected with 40 ng of CMO. M,N: Vimentin antibody staining of injected (20 ng of FMO1) and uninjected side embryo (pm, pronephric mesenchyme). O: Percentage of embryos with defects in segmentation, hypaxial muscle, and mesenchyme with total numbers of embryos analyzed above each bar. P: Embryo injected with 40 ng of FMO1 and probed for myf5 shows no change in myf5 expression levels, despite a clear reduction in myotome width (double head arrow).

Gene Clone Species Stages Anatomy
myod1.S laevis NF stage 20 paraxial mesoderm
myod1.S laevis NF stage 35 and 36 paraxial mesoderm , intersomitic region

Display additional annotations [+]
  Figure 6. Elevated FRG1 leads to somite and hypaxial muscle disruptions. A,B: Stage 20 embryos injected with 1 ng of frg1 were analyzed by in situ hybridization with pax3 (A) or myoD (B). C,D: Transverse sections of pax3 and myoD stained embryos are shown in C and D, respectively. The injected sides are denoted by ldquo i rdquo . E-J: Somite disruptions and hypaxial muscle were analyzed in stage 36 embryos injected with 500 pg of frg1 (E,I) and 1 ng of frg1 (G) compared to the uninjected sides F, J, and H, respectively, by myoD (E-H) or pax3 (I,J) in situ hybridization. A graphic summary of somite and hypaxial abnormalities for 500 pg of frg1, 1 ng of frg1, and tracer is shown in K.